Single Nucleotide Polymorphisms Influence Histological Type and Grade of Canine Malignant Mammary Tumours
In this study, the relationship between the genetic profile of 87 female dogs (i.e. single nucleotide polymorphisms [SNPs] in genes known to be involved in mammary carcinogenesis) and the histological type and grade of malignant mammary tumours was assessed. The results demonstrated a significant relationship between genetic variation in genes RAD51, BRCA2, CHEK2, HER2, CDH1, COMT and PGR and these morphological features of the mammary lesions. Specifically, SNPs in RAD51 (rs23623251 and rs23642734), CHEK2 (rs397511718), HER2 (rs24537329) and PGR (rs8875007) were related to aggressive histotypes, with moderate to high histological grade. In contrast, SNPs in BRCA2 (rs23255542), HER2 (rs24537331), CDH1 (rs852280880 and rs850805755) and COMT (rs851328636, rs853133060 and rs85346495) were associated with tumour histotypes of good prognosis and of low histological grade. These data provide preliminary evidence for a genotypic–phenotypic correlation in canine mammary tumours, highlighting the mechanisms of their genesis, development and progression.
Condition: Gastric Cancer Stage IV Intervention: Drug: Trastuzumab Sponsor: AC Camargo Cancer Center Not yet recruiting
HER2, NF-κB, and SATB1 Expression Patterns in Gastric Cancer and Their Correlation with Clinical and Pathological Parameters. Dis Markers. 2019;2019:6315936 Authors: Smolińska M, Grzanka D, Antosik P, Kasperska A, Neska-Długosz I, Jóźwicki J, Klimaszewska-Wiśniewska A Abstract Gastric cancer (GC) is currently recognized as one of the most common and fatal tumor worldwide. The identification of novel biomarkers in relation to clinical information as well as extending the knowledge on a multiple crosstalk between various oncogenic pathways implicated in GC carcinogenesis seems pivotal to...
Amplification and overexpression of human epidermal growth factor receptor 2 (HER2) in breast cancer is associated with an adverse prognosis. The introduction of trastuzumab and lapatinib has substantially improved the clinical outcomes of patients with HER2-positive breast cancer. The key element of the successful application of anti-HER2 therapies in real-world has been the selection of candidates for treatment based on the level of HER2 positivity of the tumor. HER2 status of breast cancer is clinically assessed by HER2 protein expression with immunohistochemistry (IHC) or HER2 gene amplification with in situ hybridization (ISH).
ConclusionsSmall sub-sets of breast cancers with high TMB exist and may present an opportunity for effective immunotherapeutic targeting.
Conclusion: The bioactivity prediction shows that all compounds are active to moderately active. These positive results show that it could be further investigated and explored.
CONCLUSION: As immunohistochemical analysis lacks specificity in distinguishing primary cutaneous apocrine carcinoma from a cutaneous metastasis of breast carcinoma, detailed clinical history, breast examination, adequate treatment and follow-up are necessary to confirm a diagnosis of primary cutaneous apocrine carcinoma. PMID: 31736065 [PubMed - as supplied by publisher]
Abstract Introduction: Clinicopathologic and prognostic significance of body mass index (BMI) in breast cancer (BC) patients remained conflicting. We aimed to investigate and modify the impact of BMI on clinicopathological significance and survival in western Chinese BC patients. Materials and Methods: 8,394 female BC patients from Western China Clinical Cooperation Group (WCCCG) between 2005 and 2015 were identified. Multivariable logistic regression and Cox proportion hazard regressions were used to examine the difference of clinicopathologic and survival characteristics between BMI categories. Results...
Condition: HER-2-positive Advanced Breast Cancer Interventions: Drug: GB221; Drug: Placebo control Sponsor: Genor Biopharma Co., Ltd. Recruiting
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Kadcyla® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.
New J. Chem., 2019, Advance Article DOI: 10.1039/C9NJ02893E, PaperSoonjae Jung, J. R. Anusha, Seungil Park, Kook Hyun Yu, C. Justin Raj, Byung Chul Kim The benzopyran derivative 6-amino-2-methyl-2-phenethyl-2H-benzopyran inhibits the overexpression of the protein HER2, and the64Cu-labeled compound is promising for cancer diagnosis and treatment. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry